Date: 2013-11-18
Type of information: R&D agreement
Compound: novel drug candidates against protein-protein interaction targets
Company: Novalix (France) Kyowa Hakko Kirin (Japan)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: * On January 14, 2013, NovAliXhas entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan, .
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Financial terms:
Latest news: * On November 18, 2013, NovAliX has announced that it has entered into a fragment-based drug discovery project with Kyowa Hakko Kirin Co., Ltd., Japan. This is a continuation of the alliance announced on January 14 of this year and builds upon the positive results already generated by the NovAliX biophysical platform. The companies will commence research against a new clinically significant target involving the discovery of novel small molecules that modulate protein-protein interaction. First, NovAliX will generate lead candidates using its Graffinity® screening platform. The ensuing "hits" will be elaborated by NovAliX' in-house teams of biophysical and chemistry experts. The biophysical toolbox encompasses a broad spectrum of instrumental techniques employed iteratively to support the activities of synthetic organic, computational and medicinal chemists. Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
